title: Effect of wortmannin and phorbol ester on Paramecium fluid-phase uptake in the presence of transferrin.
abstract: The kinetics of the uptake of the fluid phase marker Lucifer Yellow (LY), and its alteration by wortmannin, an inhibitor of phosphatidylinositol-3 kinase (PI-3K), and the PKC modulators: GF 109203 X, an inhibitor, and phorbol ester, an activator was studied in eukaryotic model Paramecium aurelia. Spectrophotometric quantification of LY accumulation was performed in the presence or absence of transferrin, a marker of receptor-mediated endocytosis. Internalization of LY showed a curvilinear kinetics: the high initial rate of LY uptake (575 ng LY/mg protein/hr) decreased almost 5-fold within 15 min, reaching plateau at 126 ng/mg protein/hr. Transferrin induced a small increase (7.5%) in the fluid phase uptake rate (after 5 min) followed by a small decrease at longer incubation times. Lucifer Yellow and transferrin (visualized by streptavidin-FITC) were localized in Paramecium by 3-D reconstruction by confocal microscopy. LY showed a scattered, diffuse fluorescence typical of fluid phase uptake whereas transferrin accumulated in membrane-surrounded endosomes. Wortmannin did not affect LY accumulation but decreased it when transferrin was present in the incubation medium. This suggests an effect on the transferrin uptake pathway, presumably on the stage of internalization in "mixing" endosomes to which transferrin and LY were targeted. Phorbol ester diminished LY accumulation by 22% and this effect persisted up to 25 min of incubation. PKC inhibitor did not affect LY uptake. However, in the presence of transferrin, the LY uptake increased within the first 15 minutes followed by a rapid 20% decrease in comparison to the control. Such an effect of PKC modulators suggests that PMA action on fluid phase uptake is not directly mediated by PKC.
authors.affiliation: Department of Cell Biology, Nencki Institute of Experimental Biology, Warsaw, Poland.
authors.forename: J
authors.initials: J
authors.lastname: Wiejak
authors.forename: L
authors.initials: L
authors.lastname: Surmacz
authors.forename: E
authors.initials: E
authors.lastname: Wyroba
mesh_terms: D000730:Androstadienes / Q000494:pharmacology*; D000818:Animals; D015415:Biomarkers; D004705:Endocytosis; D011992:Endosomes / Q000378:metabolism; D004789:Enzyme Activation; D007211:Indoles / Q000494:pharmacology; D007546:Isoquinolines / Q000493:pharmacokinetics*; D008301:Maleimides / Q000494:pharmacology; D010247:Paramecium / Q000187:drug effects / Q000378:metabolism; D000081082:Phosphoinositide-3 Kinase Inhibitors; D011493:Protein Kinase C / Q000037:antagonists & inhibitors / Q000378:metabolism*; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology*; D014168:Transferrin / Q000494:pharmacology*; D000077191:Wortmannin
chemical_list: D000730:Androstadienes; D015415:Biomarkers; D007211:Indoles; D007546:Isoquinolines; D008301:Maleimides; D000081082:Phosphoinositide-3 Kinase Inhibitors; D014168:Transferrin; C017475:lucifer yellow; D011493:Protein Kinase C; C070515:bisindolylmaleimide I; D013755:Tetradecanoylphorbol Acetate; D000077191:Wortmannin